Labcorp (LH) Upgraded to Buy: Here's What You Should Know
Labcorp (LH) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
LH - Labcorp Holdings Inc.
Price:
--
--
|
CONSENSUS:
Buy
DETAILS
|
PRICE TARGET:
$311.33
DETAILS
HIGH:
$334.00
LOW:
$300.00
MEDIAN:
$300.00
CONSENSUS:
$311.33
UPSIDE:
19.77%
Stock News
Should You Continue to Hold Labcorp Stock in Your Portfolio?
LH gains from specialty testing growth, acquisitions and AI initiatives, but currency swings and macro pressures remain risks.
Why Labcorp Holdings (LH) is a Top Value Stock for the Long-Term
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Labcorp Launches MyLabcorp™, a New AI-Powered Mobile App Designed to Help Consumers Understand Lab Results and Track Health Trends Over Time
MyLabcorp connects lab results, educational content and AI-enabled features in a secure, personalized mobile experience Leverages OpenAI models designed to help users understand their results, ask questions and identify patterns over time BURLINGTON, N.C., May 20, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the launch of MyLabcorp ™ , an AI-powered mobile app that brings together lab results, AI-enabled features and clinical guideline-based content in a secure, personalized mobile experience.
Labcorp and Epic Expand Collaboration to Advance Diagnostic Integration across Hospitals and Health Systems
Labcorp's full test menu will be available through Epic's Aura platform Integration builds on the successful deployment of Invitae genetic testing and accelerates access to the latest genetic and specialty diagnostics through Aura Collaboration will help reduce IT complexity, streamline lab ordering and improve access to diagnostic innovation for hospitals and health systems using Epic nationwide BURLINGTON, N.C., May 12, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced an expanded collaboration with Epic, the nation's leading electronic health record (EHR) supporting hospitals and health systems.
LH vs. CRL: Which Stock Is the Better Value Option?
Investors interested in stocks from the Medical Services sector have probably already heard of Labcorp Holdings (LH) and Charles River Laboratories (CRL). But which of these two stocks offers value investors a better bang for their buck right now?
Here's Why Labcorp (LH) Is a Great 'Buy the Bottom' Stock Now
Labcorp (LH) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
LH Stock Up in Pre-Market on Q1 Earnings & Revenue Beat, 2026 View Up
Labcorp's shares rise after Q1 beats on earnings and revenues, with growth across segments and a higher 2026 outlook signaling continued momentum.
Labcorp Holdings Inc. (LH) Q1 2026 Earnings Call Transcript
Labcorp Holdings Inc. (LH) Q1 2026 Earnings Call Transcript
Labcorp Advances As AI Investments, Core Businesses Drive Growth
Labcorp Holdings (NYSE:LH) shares are up, up 1.46%, on Thursday as the company reported strong first-quarter results and raised its full-year guidance.
Here's Why Labcorp Holdings (LH) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
Compared to Estimates, Labcorp (LH) Q1 Earnings: A Look at Key Metrics
The headline numbers for Labcorp (LH) give insight into how the company performed in the quarter ended March 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Labcorp Holdings (LH) Q1 Earnings and Revenues Top Estimates
Labcorp Holdings (LH) came out with quarterly earnings of $4.25 per share, beating the Zacks Consensus Estimate of $4.09 per share. This compares to earnings of $3.84 per share a year ago.
Labcorp raises full-year forecasts on steady diagnostics demand
Labcorp raised its full-year profit and revenue forecast on Thursday after posting quarterly results above expectations as demand for diagnostic testing remained steady.
Is Labcorp Holdings Inc (LH) 3.3% Undervalued After Q1 2026 Earnings Beat? EPS $3.35 vs $3.09 est., Revenue $3.54B vs $3.50B est.; GF Score 84/100
Q1 2026 revenue was $3.54 billion. The revenue estimate was $3,504.54 million.Diluted EPS was $3.35. The EPS estimate was $3.09.Adjusted EPS was $4.25, up 10.6
Labcorp Announces 2026 First Quarter Results; Raises Full Year 2026 Guidance
Results from Operations for first quarter 2026 versus first quarter 2025: Revenue: $3.54 billion vs. $3.35 billion, up 5.8% Diluted EPS: $3.35 vs.
Wall Street's Insights Into Key Metrics Ahead of Labcorp (LH) Q1 Earnings
Beyond analysts' top-and-bottom-line estimates for Labcorp (LH), evaluate projections for some of its key metrics to gain a better insight into how the business might have performed for the quarter ended March 2026.
Solventum (SOLV) Reports Next Week: Wall Street Expects Earnings Growth
Solventum (SOLV) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Labcorp Holdings (LH) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
Labcorp (LH) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Labcorp Launches FDA-Approved Companion Diagnostic to Identify Patients with Ovarian Cancer Eligible for KEYTRUDA®
BURLINGTON, N.C., April 22, 2026 /PRNewswire/ -- Labcorp (NYSE: LH), a global leader of innovative and comprehensive laboratory services, today announced the nationwide availability of Agilent Technologies' PD-L1 IHC 22C3 pharmDx, the only companion diagnostic approved by the U.S. Food and Drug Administration (FDA) to identify patients with platinum-resistant ovarian cancer who may be eligible for Merck's KEYTRUDA®.i KEYTRUDA (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph) are the first FDA-approved PD-1 inhibitors available as part of a complete treatment regimen for eligible patients with platinum-resistant ovarian cancer.ii Helping Patients Access Critical New Treatment Options Approximately 80% of individuals with ovarian cancer experience recurrence after initial therapy, and many develop resistance to platinum-based chemotherapy, leading to limited treatment options and poor survival outcomes.
Price Targets
Labcorp price target raised to $334 from $332 at Baird
$334.00
(was $255.97)
Eric Coldwell
·
Robert W. Baird
Labcorp price target raised to $300 from $280 at Evercore ISI
$300.00
(was $274.72)
Evercore ISI
Labcorp price target raised to $300 from $270 at Piper Sandler
$300.00
(was $285.30)
David Westenberg
·
Piper Sandler
Labcorp price target raised to $326 from $313 at Baird
$326.00
(was $276.67)
Robert W. Baird
Labcorp price target raised to $313 from $307 at Baird
$313.00
(was $259.18)
Robert W. Baird
Labcorp price target lowered to $320 from $325 at UBS
$320.00
(was $253.74)
Kevin Caliendo
·
UBS
Labcorp price target lowered to $304 from $313 at Baird
$304.00
(was $259.69)
Robert W. Baird
Leerink on Laboratory Corporation of America (LH): 'Sell-off Unwarranted'
$342.00
(was $261.62)
Michael Cherny
·
Leerink Partners
Labcorp price target raised to $325 from $305 at UBS
$325.00
(was $285.93)
UBS
Labcorp price target raised to $320 from $285 at Mizuho
$320.00
(was $283.71)
Ann Hynes
·
Mizuho Securities
Labcorp price target raised to $320 from $310 at Truist
$320.00
(was $278.42)
Truist Financial
Labcorp price target raised to $305 from $300 at Evercore ISI
$305.00
(was $279.44)
Evercore ISI
Labcorp price target raised to $290 from $275 at Barclays
$290.00
(was $279.06)
Barclays
Labcorp price target raised to $311 from $302 at Baird
$311.00
(was $276.11)
Robert W. Baird
Labcorp price target raised to $305 from $282 at UBS
$305.00
(was $264.96)
Kevin Caliendo
·
UBS
Labcorp price target raised to $275 from $250 at Barclays
$275.00
(was $258.70)
Barclays
Labcorp price target raised to $271 from $249 at Barclays
$271.00
(was $247.86)
Luke Sergott
·
Barclays
Labcorp price target lowered to $240 from $250 at Evercore ISI
$240.00
(was $224.72)
Elizabeth Anderson
·
Evercore ISI
Laboratory Corporation of America (LH) PT Raised to $265 at Jefferies
$265.00
(was $222.22)
Brian Tanquilut
·
Jefferies
Labcorp price target raised to $260 from $240 at BofA
$260.00
(was $236.00)
Michael Ryskin
·
Bank of America Securities